3rd Quarter - Report
TODD STRATEGY GROUP for BIODESIX, INC.
Firm
Client
Income
$30,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
FDA regulation of laboratory developed tests.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL New | — |
| DANIEL M TODD | — |
Medicare/Medicaid MMM
Implementation of PL 113-93 (H.R. 4302): Protecting Access to Medicare Act of 2014. Implementation of changes to Medicare payments for clinical laboratory tests. Medicare treatment of outpatient reimbursement for laboratory tests. FDA regulation of laboratory developed tests (LDTs).
| Lobbyist | Covered position, as disclosed |
|---|---|
| PAUL EDATTEL New | Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg |
| DANIEL M TODD | Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.